Rallybio’s Post

The primary endpoint of our Phase 2 NEULARK clinical trial of NEU-411 incorporates a digital biomarker and smartphone-based solution developed by Roche Information Solutions (RIS), the Roche group focused on digital health solutions. Clinical development in #Parkinsons disease (PD) has historically been challenged by symptom variability that reduces the sensitivity and reliability of clinical outcome assessments. Potential benefits of the navify® digital biomarker solution include significantly greater frequency of data measurement and more objective and precise quantification of symptoms. Learn more about Neuron23’s usage of Roche’s digital biomarker and device in our PD clinical trial here: https://lnkd.in/gUTJXeB8

𝐖𝐡𝐢𝐥𝐞 𝐦𝐨𝐬𝐭 𝐛𝐢𝐨𝐭𝐞𝐜𝐡𝐬 𝐟𝐨𝐜𝐮𝐬 𝐨𝐧 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭, 𝐀𝐮𝐬𝐩𝐞𝐫𝐁𝐢𝐨 𝐭𝐚𝐫𝐠𝐞𝐭𝐬 𝐭𝐡𝐞 𝐮𝐥𝐭𝐢𝐦𝐚𝐭𝐞 𝐩𝐫𝐢𝐳𝐞—𝐚 𝐟𝐮𝐧𝐜𝐭𝐢𝐨𝐧𝐚𝐥 𝐜𝐮𝐫𝐞. 𝐇𝐞𝐫𝐞’𝐬 𝐰𝐡𝐲 𝐭𝐡𝐢𝐬 𝐜𝐡𝐚𝐧𝐠𝐞𝐬 𝐞𝐯𝐞𝐫𝐲𝐭𝐡𝐢𝐧𝐠. AusperBio just secured $73M in Series B financing to advance its groundbreaking therapy, AHB-137, aiming for a functional cure for chronic Hepatitis B. Unlike traditional approaches that focus on managing symptoms, AusperBio’s proprietary Med-Oligo™ platform is disrupting the landscape with targeted oligonucleotide therapies. This funding will not only accelerate clinical trials but also enable global-scale operations and expansion of their therapeutic pipeline. AHB-137’s progress signifies a paradigm shift in treating one of the world’s most challenging chronic diseases. 𝐀𝐬 𝐚 𝐥𝐞𝐚𝐝𝐞𝐫 𝐢𝐧 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧, 𝐡𝐨𝐰 𝐝𝐨 𝐲𝐨𝐮 𝐬𝐞𝐞 𝐭𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐥𝐢𝐤𝐞 𝐀𝐇𝐁-137 𝐢𝐧𝐟𝐥𝐮𝐞𝐧𝐜𝐢𝐧𝐠 𝐭𝐡𝐞 𝐛𝐫𝐨𝐚𝐝𝐞𝐫 𝐥𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 𝐨𝐟 𝐜𝐡𝐫𝐨𝐧𝐢𝐜 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭? Yiming Yin, Justin Tan, Nan (Alan) Zhao, Ph.D., Yingbin (Jean) Xu, Way Tang, PhD, Jack Ding, Jack Ding, Dr. Hui Wu, Jianyu W., Mingjiu Chen Sam Fan, Sheng Liu, Yoon Pin Lim, Yerriswamy Manchi, Samuel Gan Yong Chang, Yiming Yin, Justin Tan, Leo Liang, 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐮𝐬 ▶️ https://lnkd.in/ed_mKpkF #AusperBio #BiotechInnovation #ChronicHepatitisB #FunctionalCure 

2025 is poised to be an important year for Ventus, as we advance our clinical pipeline into multiple Phase 2 proof-of-concept trials. We will initiate two Phase 2 trials for VENT-02, a novel, brain-penetrant NLRP3 inhibitor, in #Parkinson’s disease and #osteoarthritis in obese patients and two Phase 2 trials for VENT-03, a first-in-class cGAS inhibitor, in systemic #lupus erythematosus (SLE) and treatment-refractory #rheumatoidarthritis (RA). These steps bring us closer to delivering exceptional medicines for patients, and we are excited for the impactful data that will be unlocked over the next 12-18 months.

🌟 NEW EPISODE ALERT 🌟 Dive deep into the world of Idiopathic Pulmonary Fibrosis (IPF) with Dr. Victor Thannickal on our latest episode of BIO from the BAYOU. 🎙️ Learn about the symptoms, progression, and the groundbreaking drug therapies being developed to combat this devastating lung disease. 🔍 Highlights: • Understanding IPF fundamentals • Impact on patient lives • Innovative therapies from Dr. Thannickal’s lab • Latest research advancements 📲 Listen now and stay ahead in biotech developments! #Biotech #HealthcareInnovation #IPF #LungDisease #PharmaceuticalResearch ➡️ Listen to Episode 36 Now (link in comments)

This is what world class execution looks like... Ventus Therapeutics is on track to deliver 4 clinical POC readouts over the next 18 months, all in high impact, high commercial opportunity diseases with best in class molecules with differentiated mechanisms (cGAS and CNS-NLRP3).

29th September was #WorldHeartDay. To celebrate this event, we used our team’s voice and heart to spread the World Heart Federation message, raising awareness of #Cardiovascular diseases in our lives. To do that, we did #UseHeart, although ours were digital… Take a look at these 24 heart simulations from our team. As you can see, each heart is unique, which affects the complexity of replicating cardiovascular environments for drug testing. This is where ELEM Biotech’s #VirtualHearts play a crucial role. By simulating human hearts, we can enable Pharmaceutical companies to design #SMARTtrials that account for population variability, developing more personalized and effective treatments. If you want to learn more about the potentialities of #VirtualHumanTwins and understand the impact of #SMARTtrials on healthcare, contact us at contact@elem.bio. #CardiovascularHealth #VirtualHumanTwins #UseVirtualHearts

#ASCO2024 Key Abstracts in #Lymphomas *DEB:* Interim analysis of a phase III study of tucidinostat plus R-CHOP in previously untreated DLBCL with double expression of MYC and BCL2 (Abstract LBA7003). Tucidinostat, an oral HDAC inhibitor, has been evaluated in a prospective, randomized phase III study among patients with DLBCL and expression of both MYC and BCL2. Although not limited exclusively to the double-hit population, double expression has been associated with inferior outcomes with standard R-CHOP. Available at: https://lnkd.in/gEXUHmnV *ECHELON-3:* Results from the phase III trial of brentuximab vedotin plus lenalidomide and rituximab in patients with R/R DLBCL (Abstract LBA7005). Prior studies in DLBCL have shown that CD30 expression is not required for activity of brentuximab in the treatment of the disease. This randomized phase III study compared lenalidomide/rituximab with or without brentuximab, and results will inform on the benefit of this combination strategy in DLBCL. Available at: https://lnkd.in/gXjcgb24

The DESTINY-CRC02 trial: Multicenter, phase 2 evaluating the efficacy and safety of 2 doses of trastuzumab deruxtecan in patients w/pretreated HER2+ metastatic #ColorectalCancer , including those with RAS🧬mutations. The trial involved 122 patients across 53 hospitals globally, with participants receiving either dose every 21 days. The primary endpoint was the confirmed objective response rate, which was higher in the 5.4 mg/kg group (37.8%) compared to the 6.4 mg/kg group (27.5%). The 5.4 mg/kg dose demonstrated a more favorable safety profile, with fewer severe adverse events. ➡️The findings suggest that trastuzumab deruxtecan at 5.4 mg/kg is the optimal dose for this patient population, offering a promising treatment option with manageable safety concerns. Salvatore Siena Takashima Atsuo Filippo Pietrantonio Hisato Kawakami Thierry André Hung-Chih Hsu John Strickler Yongjun Cha Daniel BARRIOS

🔬 New Publication from Sven Schneider from our lab together with Sven Seys and the CHRINOSOR consortium: Real-World Effectiveness of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) We're excited to share our latest research assessing the real-world impact of dupilumab on a large CRSwNP patient cohort across six European tertiary care centers. Key Findings: Significant Symptom Improvement: Dupilumab treatment led to marked improvements in nasal polyp score (NPS), quality of life (SNOT-22), and symptom scales (smell, sinus blockage). Outcomes improved substantially by both 24 and 52 week. High Response Rates: At 52 weeks, 68.2% of patients met all 4 of the more stringent EUFOREA response criteria, underscoring the sustained, robust impact of dupilumab. This study highlights dupilumab as an effective and durable treatment option for patients with CRSwNP, regardless of comorbidities or baseline type 2 inflammation levels. https://lnkd.in/dFm3gEnW

🤔 Want to learn more about EPND and the Study #Catalogue? Looking for guidance on biofluid collection, #biobanking or #biomarker immunoassays? ➡ check out the EPND Vimeo channel, which includes videos on our platform, tools and resources: 📍 Our co-Lead Pieter Jelle Visser introduces the mission, aims and objectives of the EPND project 📍 Matthew Clement walks users through the design, features and functionalities of the extended EPND Catalogue 📍 Dr. Maike Tauchert explains current biobanking practices and outlines the EPND Best Practice guideline 📍 Charlotte Teunissen details the EPND Standard Operating Protocol (SOP) for biofluid collection and biobanking 📍 Michele Hu outlines the development of the combined Minimal Dataset SOP for cohorts across #Alzheimers disease, #Parkinsons disease and #dementia with Lewy bodies 📍 Andreasson Ulf explains how to validate #biomarker immunoassays, guided by a SOP 📍 Anna-Katharine Brem looks at best practices for #digital #biomarker collection Discover EPND ➡ https://lnkd.in/ebBZscfj Innovative Health Initiative (IHI) EFPIA - European Federation of Pharmaceutical Industries and Associations